Adriamycin-induced changes of creatine kinase activity in vivo and in cardiomyocyte culture

S. Michael Deatley; Michael Y. Aksenov; Marina V. Aksenova; Brad Jordan; John M. Carney; D. Allan Butterfield

doi:10.1016/S0300-483X(99)00039-6

Adriamycin-induced changes of creatine kinase activity in vivo and in cardiomyocyte culture

S. Michael Deatley, Michael Y. Aksenov, Marina V. Aksenova, Brad Jordan, John M. Carney, D. Allan Butterfield

Research output: Contribution to journal › Article › peer-review

52 Scopus citations

Abstract

Adriamycin (ADM) is an anthracycline anti-neoplastic agent, whose clinical effectiveness is limited by severe side effects, including cardiotoxicity. The toxic effects of ADM are likely to be the consequence of the generation of free radicals. This study demonstrates that ADM induces significant changes in the activity of the oxidative sensitive enzyme creatine kinase (CK) in the heart in vivo and in a cardiomyocyte culture model. The changes observed are likely to reflect the ability of ADM to damage the plasma membrane of cardiac cells and to induce the direct inactivation of CK. The role for ADM-derived free radicals is one of the possible mechanisms for the CK inactivation observed during the ADM treatment. Copyright (C) 1999 Elsevier Science Ireland Ltd.

Original language	English
Pages (from-to)	51-62
Number of pages	12
Journal	Toxicology
Volume	134
Issue number	1
DOIs	https://doi.org/10.1016/S0300-483X(99)00039-6
State	Published - May 3 1999

Bibliographical note

Funding Information:
This work was supported in part by NIH grants (AG-10836; AG-05119) and by a grant from Centaur Pharmaceuticals.

Keywords

Adriamycin
Cardiomyocytes
Cardiotoxicity
Creatine kinase
Oxygen free radicals

ASJC Scopus subject areas

Toxicology

Access to Document

10.1016/S0300-483X(99)00039-6

Cite this

@article{831c14b1d2e7470da249eb99e1e2cd0b,

title = "Adriamycin-induced changes of creatine kinase activity in vivo and in cardiomyocyte culture",

abstract = "Adriamycin (ADM) is an anthracycline anti-neoplastic agent, whose clinical effectiveness is limited by severe side effects, including cardiotoxicity. The toxic effects of ADM are likely to be the consequence of the generation of free radicals. This study demonstrates that ADM induces significant changes in the activity of the oxidative sensitive enzyme creatine kinase (CK) in the heart in vivo and in a cardiomyocyte culture model. The changes observed are likely to reflect the ability of ADM to damage the plasma membrane of cardiac cells and to induce the direct inactivation of CK. The role for ADM-derived free radicals is one of the possible mechanisms for the CK inactivation observed during the ADM treatment. Copyright (C) 1999 Elsevier Science Ireland Ltd.",

keywords = "Adriamycin, Cardiomyocytes, Cardiotoxicity, Creatine kinase, Oxygen free radicals",

author = "Deatley, {S. Michael} and Aksenov, {Michael Y.} and Aksenova, {Marina V.} and Brad Jordan and Carney, {John M.} and Butterfield, {D. Allan}",

note = "Funding Information: This work was supported in part by NIH grants (AG-10836; AG-05119) and by a grant from Centaur Pharmaceuticals.",

year = "1999",

month = may,

day = "3",

doi = "10.1016/S0300-483X(99)00039-6",

language = "English",

volume = "134",

pages = "51--62",

number = "1",

}

TY - JOUR

T1 - Adriamycin-induced changes of creatine kinase activity in vivo and in cardiomyocyte culture

AU - Deatley, S. Michael

AU - Aksenov, Michael Y.

AU - Aksenova, Marina V.

AU - Jordan, Brad

AU - Carney, John M.

AU - Butterfield, D. Allan

N1 - Funding Information: This work was supported in part by NIH grants (AG-10836; AG-05119) and by a grant from Centaur Pharmaceuticals.

PY - 1999/5/3

Y1 - 1999/5/3

N2 - Adriamycin (ADM) is an anthracycline anti-neoplastic agent, whose clinical effectiveness is limited by severe side effects, including cardiotoxicity. The toxic effects of ADM are likely to be the consequence of the generation of free radicals. This study demonstrates that ADM induces significant changes in the activity of the oxidative sensitive enzyme creatine kinase (CK) in the heart in vivo and in a cardiomyocyte culture model. The changes observed are likely to reflect the ability of ADM to damage the plasma membrane of cardiac cells and to induce the direct inactivation of CK. The role for ADM-derived free radicals is one of the possible mechanisms for the CK inactivation observed during the ADM treatment. Copyright (C) 1999 Elsevier Science Ireland Ltd.

AB - Adriamycin (ADM) is an anthracycline anti-neoplastic agent, whose clinical effectiveness is limited by severe side effects, including cardiotoxicity. The toxic effects of ADM are likely to be the consequence of the generation of free radicals. This study demonstrates that ADM induces significant changes in the activity of the oxidative sensitive enzyme creatine kinase (CK) in the heart in vivo and in a cardiomyocyte culture model. The changes observed are likely to reflect the ability of ADM to damage the plasma membrane of cardiac cells and to induce the direct inactivation of CK. The role for ADM-derived free radicals is one of the possible mechanisms for the CK inactivation observed during the ADM treatment. Copyright (C) 1999 Elsevier Science Ireland Ltd.

KW - Adriamycin

KW - Cardiomyocytes

KW - Cardiotoxicity

KW - Creatine kinase

KW - Oxygen free radicals

UR - http://www.scopus.com/inward/record.url?scp=0033046059&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033046059&partnerID=8YFLogxK

U2 - 10.1016/S0300-483X(99)00039-6

DO - 10.1016/S0300-483X(99)00039-6

M3 - Article

C2 - 10413188

AN - SCOPUS:0033046059

SN - 0300-483X

VL - 134

SP - 51

EP - 62

JO - Toxicology

JF - Toxicology

IS - 1

ER -

Adriamycin-induced changes of creatine kinase activity in vivo and in cardiomyocyte culture

Abstract

Bibliographical note

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this